-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since diabetes requires lifelong medication, the entire market has formed a huge demand
.
Statistics show that in the first half of 2021, the market size of China's public medical institutions' terminal diabetes medications exceeded 27 billion yuan
.
According to the industry, the huge market demand is attracting the active deployment of pharmaceutical companies
.
In recent years, Chinese pharmaceutical companies have gradually appeared in the research and development queue of new diabetes drugs, including Shanghai Renhui Biopharmaceuticals, Hausen Pharmaceuticals, Microchip Biopharmaceuticals, Hengrui Pharmaceuticals, Hualing Pharmaceuticals, Tonghua Dongbao, East China Pharmaceuticals, Ganli Pharmaceuticals, etc.
.
Take Hengrui Pharmaceuticals as an example.
In recent years, Hengrui Pharmaceuticals has a comprehensive layout of innovative drugs in the field of hypoglycemic drugs and has blossomed in many ways
.
According Insight database shows, Henry 10 DRUG models of diabetes (including improved new) development which covers innovation small molecule drugs, insulin, GLP-1, the compound preparations
.
Among them, in the field of small molecules, Hengrui Pharmaceuticals has made rapid progress in DPP4 inhibitor Repagliptin and SGLT2 inhibitor Hengligliflozin.
Currently, both of these products have been declared for the market
.
In addition, on November 17, Hengrui Medicine's super fast-acting insulin HR011408 started clinical trials, and new news in the field of hypoglycemic drugs came again
.
According to data, HR011408 injection is a new and improved drug of fast-acting insulin.
After subcutaneous injection, it has faster insulin absorption and blood sugar lowering speed, which can better simulate the secretion of insulin during meals under physiological conditions.
It is clinically intended for subcutaneous injection Treat adult diabetes
.
Super fast-acting insulin injection belongs to a new generation of fast-acting insulin analogue products.
It has the advantages of more rapid onset of insulin and can be closer to the physiological insulin secretion after a meal
.
The diabetes market is huge, and data shows that the global hypoglycemic drug market has reached 50.
98 billion U.
S.
dollars in 2019
.
The scale of the terminal diabetes medication market in public medical institutions in China has exceeded 27 billion yuan in the first half of this year
.
In the field of hypoglycemic drugs, pharmaceutical companies are actively deploying to seize market opportunities
.
With the continuous deployment of pharmaceutical companies, the field of hypoglycemic drugs also continues to usher in new progress
.
It is understood that since the beginning of this year, domestically produced Class 1 hypoglycemic new drugs have ushered in many new developments.
Among them, Microchip's Siglipta has been approved and is known as the first domestic new diabetes drug in China; Hualing's Dozaglietin has been approved.
Approved for production, it is the world’s leading innovative drug.
.
.
According to incomplete statistics, there are currently more than 50 domestically-made Class 1 hypoglycemic new drugs in the clinical application and above stage, of which 14 have entered the phase III clinical and above stage.
Focus on the three major targets of DPP-4, GLP-1 and SGLT-2
.
From the perspective of domestically produced Class 1 new diabetes drugs, three have been approved for marketing.
In addition to the Chipglita Sodium Tablets approved for marketing this year, there are also Shanghai Renhui Biopharmaceuticals approved in 2015.
Benaglutide injection, the polyethylene glycol loxenatide injection of Hausen Pharmaceuticals approved in 2017
.
Among them, Siglipta Sodium Tablets of Chipset Biosciences is a peroxisome proliferator-activated receptor full agonist, which can improve insulin resistance, dyslipidemia and reduce the risk of coronary artery disease, reduce fatty liver and reduce triglycerides , Improve energy metabolism
.
According to the industry, the continuous introduction of new domestic hypoglycemic drugs has intensified competition in all aspects, and at the same time, the space for imported drugs has been gradually squeezed, and the market structure has undergone subtle changes
.
However, some people pointed out that the current hypoglycemic drug market in China is mainly dominated by traditional drugs, innovative drugs DPP-4 inhibitors (dipeptidyl peptidase 4 inhibitors), GLP-1 receptor agonists (glucagon-like Peptide 1 receptor agonists) and SGLT-2 inhibitors (sodium-glucose cotransporter 2 inhibitors) account for far less than other developed countries, and they are still in their infancy
.
.
Statistics show that in the first half of 2021, the market size of China's public medical institutions' terminal diabetes medications exceeded 27 billion yuan
.
According to the industry, the huge market demand is attracting the active deployment of pharmaceutical companies
.
In recent years, Chinese pharmaceutical companies have gradually appeared in the research and development queue of new diabetes drugs, including Shanghai Renhui Biopharmaceuticals, Hausen Pharmaceuticals, Microchip Biopharmaceuticals, Hengrui Pharmaceuticals, Hualing Pharmaceuticals, Tonghua Dongbao, East China Pharmaceuticals, Ganli Pharmaceuticals, etc.
.
Take Hengrui Pharmaceuticals as an example.
In recent years, Hengrui Pharmaceuticals has a comprehensive layout of innovative drugs in the field of hypoglycemic drugs and has blossomed in many ways
.
According Insight database shows, Henry 10 DRUG models of diabetes (including improved new) development which covers innovation small molecule drugs, insulin, GLP-1, the compound preparations
.
Among them, in the field of small molecules, Hengrui Pharmaceuticals has made rapid progress in DPP4 inhibitor Repagliptin and SGLT2 inhibitor Hengligliflozin.
Currently, both of these products have been declared for the market
.
In addition, on November 17, Hengrui Medicine's super fast-acting insulin HR011408 started clinical trials, and new news in the field of hypoglycemic drugs came again
.
According to data, HR011408 injection is a new and improved drug of fast-acting insulin.
After subcutaneous injection, it has faster insulin absorption and blood sugar lowering speed, which can better simulate the secretion of insulin during meals under physiological conditions.
It is clinically intended for subcutaneous injection Treat adult diabetes
.
Super fast-acting insulin injection belongs to a new generation of fast-acting insulin analogue products.
It has the advantages of more rapid onset of insulin and can be closer to the physiological insulin secretion after a meal
.
The diabetes market is huge, and data shows that the global hypoglycemic drug market has reached 50.
98 billion U.
S.
dollars in 2019
.
The scale of the terminal diabetes medication market in public medical institutions in China has exceeded 27 billion yuan in the first half of this year
.
In the field of hypoglycemic drugs, pharmaceutical companies are actively deploying to seize market opportunities
.
With the continuous deployment of pharmaceutical companies, the field of hypoglycemic drugs also continues to usher in new progress
.
It is understood that since the beginning of this year, domestically produced Class 1 hypoglycemic new drugs have ushered in many new developments.
Among them, Microchip's Siglipta has been approved and is known as the first domestic new diabetes drug in China; Hualing's Dozaglietin has been approved.
Approved for production, it is the world’s leading innovative drug.
.
.
According to incomplete statistics, there are currently more than 50 domestically-made Class 1 hypoglycemic new drugs in the clinical application and above stage, of which 14 have entered the phase III clinical and above stage.
Focus on the three major targets of DPP-4, GLP-1 and SGLT-2
.
From the perspective of domestically produced Class 1 new diabetes drugs, three have been approved for marketing.
In addition to the Chipglita Sodium Tablets approved for marketing this year, there are also Shanghai Renhui Biopharmaceuticals approved in 2015.
Benaglutide injection, the polyethylene glycol loxenatide injection of Hausen Pharmaceuticals approved in 2017
.
Among them, Siglipta Sodium Tablets of Chipset Biosciences is a peroxisome proliferator-activated receptor full agonist, which can improve insulin resistance, dyslipidemia and reduce the risk of coronary artery disease, reduce fatty liver and reduce triglycerides , Improve energy metabolism
.
According to the industry, the continuous introduction of new domestic hypoglycemic drugs has intensified competition in all aspects, and at the same time, the space for imported drugs has been gradually squeezed, and the market structure has undergone subtle changes
.
However, some people pointed out that the current hypoglycemic drug market in China is mainly dominated by traditional drugs, innovative drugs DPP-4 inhibitors (dipeptidyl peptidase 4 inhibitors), GLP-1 receptor agonists (glucagon-like Peptide 1 receptor agonists) and SGLT-2 inhibitors (sodium-glucose cotransporter 2 inhibitors) account for far less than other developed countries, and they are still in their infancy
.
